Modality
mRNA
MOA
BCMA ADC
Target
Cl18.2
Pathway
Complement
Endometrial Ca
Development Pipeline
Preclinical
Mar 2023
→ May 2028
PreclinicalCurrent
NCT07466038
1,129 pts·Endometrial Ca
2023-03→2028-05·Not yet recruiting
1,129 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-202.1y awayInterim· Endometrial Ca
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Preclinical
Not yet…
Catalysts
Interim
2028-05-20 · 2.1y away
Endometrial Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07466038 | Preclinical | Endometrial Ca | Not yet recr... | 1129 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα |